All News

RA erosions bone ACR

Can Targeting RANKL in RA Heal Erosions?

d MedPage Today

Treatment with denosumab (Prolia) helped heal bone erosions over 2 years among patients with rheumatoid arthritis whose disease activity was well controlled, researchers reported.

Read Article
stop.smoking.jpg

Implementing Smoking Cessation Programs

d Jack Cush, MD

Rheumatologists are keen to the effects of smoking (increased arthritis risk, worse outcomes, blunted DMARD responses, added cardiopulmonary risks), but often do not have the resources or plan to encourage or implement smoking cessation from the rheumatology clinic. A new study details the success of a rheumatology staff‐driven protocol, Quit Connect, to increase the rate of electronic referrals to free, state‐run tobacco quit lines.

Read Article
medical.problems.jpg

Rheumatology Care Derailed by COVID-19

d Jack Cush, MD

A survey study from the  ArthritisPower PPRN or CreakyJoints database shows that during the COVID-19 pandemic patient care was substantially affected in unforeseen ways.

Read Article
COVID19.needles.Rx_.jpg

Reactogenicity Following mRNA COVID-19 Vaccines

d Jack Cush, MD

JAMA has published the real-world reporting of mRNA vaccine side effects (reactogenicity) gathered from CDC V-safe Surveillance system and shows that local and systemic reactions were often mild and transient and most commonly seen during the first day following their second dose.

Read Article
cushknees1.jpg

Cost Efficacy of Knee Replacement in Obese Osteoarthritis

d Jack Cush, MD

Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. The only potential limitation is a greater risk for adverse events in those with a body mass index (BMI) of 40 kg/m2 or greater.

Read Article
News Feature: Cost Efficacy of Knee Replacement in Obese Osteoarthritis Total knee replacement (TKR) in obese patients with end-stage knee osteoarthritis appears to be a beneficial and cost-effective strategy for treating. https://t.co/tnzqufjhBb https://t.co/6lNf27lrTL

Links:

Dr. John Cush RheumNow ( View Tweet)
A Patient-Centered Exploration of Axial Involvement in SpA Sponsored by Novartis Medical Affairs Listen to a medical expert differentiate axial involvement within the spectrum of spondyloarthritis. https://t.co/o2q5pTP3WD https://t.co/fi0CQqxVmr

Links:

Dr. John Cush RheumNow ( View Tweet)
Have you listened to last week's podcast? It's available wherever podcasts are available. Upadacitinib Wins in PsA https://t.co/Pd7QG6SsmJ https://t.co/3onAtZyoTt

Links:

Dr. John Cush RheumNow ( View Tweet)
From @DrPetryna for #RNL2021 ------ Dr. Buttgereit on steroids in RA: 2.5 mg/d of prednisone increase total steroid amount in the body by 100% - great therapeutic effect but comes w/plethora of side effects. Q: how do you feel out long term low dose steroids for RA?"

Dr. John Cush RheumNow ( View Tweet)

News Feature: Rituximab in Systemic Sclerosis? A recent metanalysis suggests that rituximab may improve skin score and disease activity indices (DAS, mRSS) while stabilizing organ involvement in SSc patients. https://t.co/lH7aP7ht10 https://t.co/UdV8NRHxdC

Links:

Dr. John Cush RheumNow ( View Tweet)
Axial Involvement in Spondyloarthritis: A Patient-Centered Exploration Sponsored by Novartis Medical Affairs Listen to Ethan Craig, MD, MPH discuss 3 of his patient cases to identify and differentiate axial involvement within the spectrum of SpA. https://t.co/o2q5pTP3WD https://t.co/su41ECWslk

Links:

Dr. John Cush RheumNow ( View Tweet)
Algorithm for the diagnostic approach of patients with joint pain - developed by PANLAR rheumatologists from 18 countries using a delphi method. Open read https://t.co/GyyfStD8Xi

Links:

Dr. John Cush RheumNow ( View Tweet)

From @KDAO2011-- "Is it better to taper the steroids or leave it? SEMIRA study. Tapering off low dose steroids cause more flares and more treatment side effects. Dr. Buttgereit says keep your low dose steroids (prednisone 5 mg/day or less) https://t.co/RAYkVxGO9N #RNL2021"

Links:

Dr. John Cush RheumNow ( View Tweet)

CDC updates its COVID Comorbid Dz list to include type 1 diabetes (& NIDDMA), mod-severe asthma, liver Dz, dementia , stroke/cerebrovascular disease, HIV infxn, cystic fibrosis, obesity, substance use disorders (NOT ARTHRITIS, PSORIASIS) https://t.co/LbVMVGf4IR

Links:

Dr. John Cush RheumNow ( View Tweet)

Cox-2 inhibition (Celebrex 200 mg bid) added to standard chemoRx (FolFox) in pts w/ stage III colon cancer failed to improve survival at 3 yrs - DB, RCT vs placebo; 3 yrs Dz free survival was Celecoxib 76% vs PBO 73% (HR 0.89; 95% CI, 0.76-1.03; P = .12) https://t.co/81L33QLa9d https://t.co/EQXgwMcgtd

Links:

Dr. John Cush RheumNow ( View Tweet)
News Feature: US Senate Introduces the Safe Step Act #RheumNow https://t.co/5SPTIXnJCS https://t.co/DtmrlJMXL9

Links:

Dr. John Cush RheumNow ( View Tweet)
Beijing study of 207 RA patients starting DMARD and steroids (GC) shows after 3 years only 59% D/C GC (mean was 24 mos). Odds of stopping GC were 10% @ 6mos, 27% @Yr1, 48% @Yr 2 and 59% at 3 years. https://t.co/E2RchB9IAs https://t.co/uDEAqaM8GC

Links:

Dr. John Cush RheumNow ( View Tweet)
Interesting case with unilateral sacroilitis - potential mimics include: Paget disease, diffuse idiopathic skeletal hyperostosis, sarcoidosis, infections [3], and also bone and hematologic tumors. What did this man have? https://t.co/Uu0kJxeJtn

Links:

Dr. John Cush RheumNow ( View Tweet)

New podcast up! Download wherever podcasts are available. Upadacitinib Wins in PsA Dr Jack Cush reviews the news and Journal reports and takes "Back Talk" questions from viewers. https://t.co/ZMAUgn10dU https://t.co/QTDqZW3GgG

Links:

Dr. John Cush RheumNow ( View Tweet)
Another study suggests poorer outcomes in Rheum pts on Rituximab. French Cohort study of 1090 inflammatory rheumatic MSK pts -13% w/ severe COVID-19 & 8% who died. 63 RTX pts had more severe disease, longer hosp stays & more death (21% vs 7%) https://t.co/5UCvFeVWRS

Links:

Dr. John Cush RheumNow ( View Tweet)

×